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Bile acids function as signaling molecules. As such they
are involved in cellular immunological processes mainly
mediating anti-inflammatory effects. They suppress cell-
mediated innate and adaptive immunity through different
signaling pathways, e.g. mediated by the nuclear bile acid
receptor farnesoid x receptor (FXR) or the G-coupled
receptor TGR5 at the outer plasma membrane. In the
past it became increasingly evident that bile acids also
modulate viral replication, which is reviewed herein.
Bile acids and interferon signaling
Interferons are central antiviral cytokines, which in part
transmit their antiviral capacity via expression of antiviral
proteins like ds-RNA-activated protein kinase (PKR), 2´5´
oligoadenylate synthase (OAS) and myxovirus resistance
protein A (MxA). Bile acids impair interferon-a and b sig-
naling in hepatocytes, NK cells, macrophages and lympho-
cytes. Results of our group showed that in case of
hepatocytes hydrophobic bile acids blunt IFNa-dependent
JAK1 and Tyk2 activation. These effects of bile acids on
IFN-signaling may limit the therapeutic use of IFNs in
hepatitis B and hepatitis C treatment [1].
Bile acids and HCV
The success of HCV therapy with IFN is dependent on
serum bile acid levels, as in patients with high serum
levels IFN therapy shows higher failing rates. Chang et
al. showed that low concentrations of unconjugated bile
acids [deoxycholic acid (DCA)/ chenodeoxycholic acid
(CDC)] and very high concentrations of the conjugated
bile acid glycochenodeoxycholic acid (GCDC) increase
HCV RNA replication in HCV genotype 1b replicon-
harboring GS4.1 cells. Importantly, high concentrations
of the therapeutically used hydrophilic ursodeoxycholic
acid may also induce a pro-viral effect [2], however differ-
ent studies in HCV patients show lower transaminases
levels without changes in virus load in response to urso-
deoxycholic acid treatment. In another study, the proviral
effect of DCA and CDC on HCV was shown in HCV
genotype 1b transfected Huh-7 cells, where conjugated
forms of these bile acids do not mediate pro-viral effects
[3]. A disadvantage of both studies is the usage of cells
that did not express the bile acid transporter sodium
taurocholate cotransporting polypeptide (NTCP), which
is essential for import of conjugated bile acids, so that
the effect of conjugated bile acids on HCV replication
could not be analyzed clearly. Both studies showed that
the pro-viral effect of bile acids is dependent on FXR
activation. Furthermore inhibition of FXR activity
reduced HCV RNA replication of genotype R1a and R1b
but not R2a independently of bile acid treatment [3]. In
HCV infected cells extracellular signal- regulated kinase
(Erk) is activated and lead to cell cycles with extended
S-phases, which had a positive effect on HCV replication.
Patton et al. showed that the pro-viral effect of bile acids
on HCV genotype 1a and 1b is dependent on epidermal
growth factor receptor (EGFR)/ERK pathway activation
that results in a prolonged S phase [4]. Only one study
characterized the pro-viral effect of bile acids in HCV life
cycle and showed an induction of viral RNA-replication,
without effecting viral entry or RNA translation. Further-
more, bile acids did not increase the abundance of cell
free virus particles, but particles seem to be more infec-
tive than virus particles from untreated cells [5]. The
choice of the viral system, the used cell lines or the usage
of partial or whole HCV genome seem to have a signifi-
cant influence on bile acid effects on virus replication, as
genotype 2a replicon harboring cells show no pro-viral
effect in response to bile acids [3], while HCV replication
could be induced by bile acids after HCV genotype 2a
genome transfection [5].
Bile acids and HBV
Hepatitis B virus (HBV) only replicates in the liver,
probably due to the fact that NTCP is the entry receptor
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for HBV and replication is dependent on liver enriched
transcription factors as hepatocyte nuclear factor 4a, liver
receptor homolog 1, estrogen-related receptor or heterodi-
mers of retinoid X receptor (RXRa) with FXRa or peroxi-
some proliferator- activated receptor [6]. Two binding
sites of FXR and RXRa heterodimers are localized in the
HBV enhancer 2 and core promoter region. Transfection
of Huh-7 cells with FXRa and a luciferase construct carry-
ing the enhancer 2 and core promoter region of HBV lead
to an induction of luciferase activity, which can be
increased by CDC and RXRa co-transfection [7]. Addi-
tional to FXR dependent activation of HBV enhancer 2 by
bile acids, CDC treatment leads to JNK/cJun and HBV
enhancer 1 activation that also result in HBV enhancer 2
induction. In contrast, bile acids induce small heterodimer
partner (SHP), which mediates inhibitory effects on HBV
replication. Recently it was shown that the activation of
RXRa or FXR alone is sufficient to induce replication of
HBV [8]. An in vivo study with HBV transgenic mice,
which were fed with 1% cholic acid, showed only slight
effects of bile acid feeding on HBV transcripts. Notably,
bile acids feeding only induced HBV in male mice, while it
had no effect on virus replication in female mice [6].
In summary, bile acids activate multiple signaling path-
ways and transcription factors to induce or inhibit virus
replication in the liver and the intestine. It would be
interesting to determine if other viruses that preferen-
tially replicate in the liver, such as hepatitis A virus, hepa-
titis D virus and hepatitis E virus, are also affected by bile
acids and have developed mechanisms to survive or even
benefit from bile acid signaling. Moreover, bile acids
modulate cell signaling in the gut and immune cells, so
that further effects of bile acids on virus replication are
also probable.
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